Avidity Partners Management LP
- SEC CIK
- 0001791827
- Latest filing
- Aug 14, 2026
Holdings in Q2 2022
Holdings as of Jun 30, 2022, filed Aug 15, 2022. Long positions only; changes compare share counts with Q1 2022.
- Positions
- 82
- −9 vs. Q1 2022
- Portfolio value
- $4.36B
- −$150.2M (−3.3%) vs. Q1 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| AZNAstraZeneca PLC | SPONSORED ADR | 3,499,000 | $231.2M | 5.3% | −201,000−5.4% | Reduced | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 793,000 | $223.5M | 5.1% | +247,400+45.3% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 572,500 | $216.9M | 5.0% | +396,500+225.3% | Added | History |
| ELVElevance Health, Inc. | Stock | 441,000 | $212.8M | 4.9% | +41,600+10.4% | Added | History |
| AVTRAvantor, Inc. | COM | 6,652,700 | $206.9M | 4.7% | +984,400+17.4% | Added | History |
| LLYEli Lilly & Co | Stock | 610,000 | $197.8M | 4.5% | +610,000 | New | History |
| HUMHumana Inc | Stock | 412,300 | $193.0M | 4.4% | +213,400+107.3% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 725,600 | $171.0M | 3.9% | +6,654+0.9% | Added | History |
| JNJJohnson & Johnson | Stock | 900,200 | $159.8M | 3.7% | +546,200+154.3% | Added | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 1,856,900 | $148.1M | 3.4% | +725,500+64.1% | Added | History |
| NBIXNeurocrine Biosciences Inc | Stock | 1,467,600 | $143.1M | 3.3% | +307,600+26.5% | Added | History |
| ARVNArvinas, Inc. | COM | 3,355,623 | $141.2M | 3.2% | +440,323+15.1% | Added | History |
| State Street SPDR S&P Biotech ETF78464A870 | ETF | 1,875,000 | $139.3M | 3.2% | +1,435,000+326.1% | Added | – |
| MCKMcKesson Corp | Stock | 388,800 | $126.8M | 2.9% | +199,300+105.2% | Added | History |
| UNHUnitedHealth Group Inc | Stock | 242,200 | $124.4M | 2.9% | −17,400−6.7% | Reduced | History |
| ABBVAbbVie Inc. | Stock | 755,000 | $115.6M | 2.7% | −711,100−48.5% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 5,450,000 | $104.9M | 2.4% | +626,600+13.0% | Added | History |
| CTLTCatalent, Inc. | COM | 955,000 | $102.5M | 2.4% | +173,000+22.1% | Added | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 3,585,881 | $100.8M | 2.3% | +408,882+12.9% | Added | History |
| SGENSeagen Inc. | COM | 550,000 | $97.3M | 2.2% | +450,000+450.0% | Added | History |
| BSXBoston Scientific Corp | Stock | 2,525,000 | $94.1M | 2.2% | +1,328,900+111.1% | Added | History |
| BIIBBiogen Inc. | COM | 440,566 | $89.8M | 2.1% | +75,566+20.7% | Added | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 1,479,500 | $88.3M | 2.0% | +610,500+70.3% | Added | History |
| ACHCAcadia Healthcare Company, Inc. | COM | 1,035,000 | $70.0M | 1.6% | +1,035,000 | New | History |
| NTLAIntellia Therapeutics, Inc. | COM | 1,125,194 | $58.2M | 1.3% | +735,119+188.5% | Added | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 1,000,000 | $55.0M | 1.3% | −95,000−8.7% | Reduced | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 1,438,999 | $50.7M | 1.2% | +483,999+50.7% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 1,350,000 | $50.4M | 1.2% | −13,800−1.0% | Reduced | History |
| NTRANatera, Inc. | COM | 1,369,100 | $48.5M | 1.1% | +69,100+5.3% | Added | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 775,504 | $44.3M | 1.0% | +775,504 | New | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 2,972,947 | $41.0M | 0.9% | +282,947+10.5% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 4,265,000 | $39.4M | 0.9% | +580,000+15.7% | Added | – |
| ALTAltimmune, Inc. | COM NEW | 2,981,000 | $34.9M | 0.8% | +116,000+4.0% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 4,050,000 | $33.5M | 0.8% | +532,000+15.1% | Added | History |
| Avidity Biosciences, Inc.05370A108 | COM | 2,080,200 | $30.2M | 0.7% | +35,200+1.7% | Added | – |
| KRTXKaruna Therapeutics, Inc. | COM | 204,570 | $25.9M | 0.6% | +204,570 | New | History |
| RVMDRevolution Medicines, Inc. | COM | 1,325,000 | $25.8M | 0.6% | +1,325,000 | New | History |
| ARK ETF Tr00214Q302 | GENOMIC REV ETF | 750,000 | $23.6M | 0.5% | +750,000 | New | – |
| VIRVir Biotechnology, Inc. | COM | 758,211 | $19.3M | 0.4% | −21,789−2.8% | Reduced | History |
| NKTXNkarta, Inc. | COM | 1,414,082 | $17.4M | 0.4% | +1,414,082 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 1,919,800 | $16.2M | 0.4% | −26,200−1.3% | Reduced | History |
| CRBUCaribou Biosciences, Inc. | COM | 2,950,000 | $16.0M | 0.4% | +130,933+4.6% | Added | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 1,200,000 | $15.8M | 0.4% | +1,200,000 | New | History |
| NUVBNuvation Bio Inc. | COM CL A | 4,855,000 | $15.7M | 0.4% | −60.0% | Reduced | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,392,300 | $15.4M | 0.4% | −4,650,919−77.0% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 450,000 | $13.7M | 0.3% | +450,000 | New | History |
| SIBNSI-BONE, Inc. | COM | 1,000,000 | $13.2M | 0.3% | 00.0% | Unchanged | History |
| SPNESeaSpine Holdings Corp | COM | 2,010,000 | $11.4M | 0.3% | 00.0% | Unchanged | History |
| ATECAlphatec Holdings, Inc. | COM NEW | 1,715,000 | $11.2M | 0.3% | −1,020,600−37.3% | Reduced | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 215,000 | $9.72M | 0.2% | +5,000+2.4% | Added | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 62,000 | $9.67M | 0.2% | +62,000 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 998,565 | $8.50M | 0.2% | −208,435−17.3% | Reduced | History |
| EPIXESSA Pharma Inc. | COM NEW | 2,460,000 | $7.75M | 0.2% | 00.0% | Unchanged | History |
| IPSCCentury Therapeutics, Inc. | COM | 865,000 | $7.27M | 0.2% | 00.0% | Unchanged | History |
| ERASErasca, Inc. | COM | 995,000 | $5.54M | 0.1% | 00.0% | Unchanged | History |
| CYTCyteir Therapeutics, Inc. | COM | 1,850,000 | $5.53M | 0.1% | 00.0% | Unchanged | History |
| ANTXAN2 Therapeutics, Inc. | COM | 688,330 | $5.33M | 0.1% | 00.0% | Unchanged | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,000,000 | $5.30M | 0.1% | 00.0% | Unchanged | History |
| Medicus Sciences AcquisitionG5960S108 | CL A SHS | 520,000 | $5.09M | 0.1% | 00.0% | Unchanged | – |
| BCLS Acquisition CorpG0904B105 | COM CL A | 500,000 | $4.95M | 0.1% | 00.0% | Unchanged | – |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 500,000 | $4.91M | 0.1% | 00.0% | Unchanged | History |
| Panacea Acquisition Corp. IIG6882C106 | CL A SHS | 500,000 | $4.88M | 0.1% | 00.0% | Unchanged | – |
| SSentinelOne, Inc. | CL A | 204,500 | $4.77M | 0.1% | 00.0% | Unchanged | History |
| ISEEIVERIC bio, Inc. | COM | 430,117 | $4.14M | 0.1% | −6,045,283−93.4% | Reduced | History |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 400,000 | $3.98M | 0.1% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 813,640 | $3.69M | 0.1% | +92,640+12.8% | Added | History |
| HYPRHyperfine, Inc. | COM CL A | 1,503,754 | $3.35M | 0.1% | 00.0% | Unchanged | History |
| CMAXCareMax, Inc. | COM CL A | 755,329 | $2.74M | 0.1% | 00.0% | Unchanged | History |
| PHASPhaseBio Pharmaceuticals Inc | COM | 4,405,000 | $2.64M | 0.1% | 00.0% | Unchanged | History |
| Field Trip Health Ord31656R102 | COM | 2,976,000 | $2.50M | 0.1% | 00.0% | Unchanged | – |
| ONCSOncosec Medical Inc | COM | 2,945,000 | $2.19M | 0.1% | 00.0% | Unchanged | History |
| OTICOtonomy, Inc. | COM | 1,000,000 | $2.08M | <0.1% | −349,905−25.9% | Reduced | History |
| PROKProkidney Corp. | CLASS A ORD SHS | 200,000 | $1.99M | <0.1% | 00.0% | Unchanged | History |
| AKLIAkili, Inc. | CLASS A ORD SHS | 200,000 | $1.98M | <0.1% | 00.0% | Unchanged | History |
| LENZLENZ Therapeutics, Inc. | COM | 710,000 | $1.95M | <0.1% | 00.0% | Unchanged | History |
| DNABSocial Capital Suvretta Holdings Corp. II | CLASS A ORD SHS | 200,000 | $1.94M | <0.1% | 00.0% | Unchanged | History |
| DNADSocial Capital Suvretta Holdings Corp. IV | CLASS A ORD SHS | 200,000 | $1.94M | <0.1% | 00.0% | Unchanged | History |
| SCYXScynexis Inc | COM NEW | 959,524 | $1.78M | <0.1% | +415,481+76.4% | Added | History |
| WGSGeneDx Holdings Corp. | COMMON STOCK | 950,000 | $1.20M | <0.1% | 00.0% | Unchanged | History |
| SNCEScience 37 Holdings, Inc. | COM | 430,000 | $864.0K | <0.1% | 00.0% | Unchanged | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 99,999 | $28.0K | <0.1% | 00.0% | Unchanged | – |
| Medicus Sciences AcquisitionG5960S124 | *W EXP 02/12/202 | 57,770 | $10.0K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q1 2022 (19)
Positions held at the end of Q1 2022 that are gone from this filing.
| Security | Class | Shares in Q1 2022 | Value in Q1 2022 | % of portfolio in Q1 2022 | History |
|---|---|---|---|---|---|
| MRKMerck & Co., Inc. | Stock | 2,370,000 | $194.5M | 4.3% | History |
| BAXBaxter International Inc | Stock | 1,915,500 | $148.5M | 3.3% | History |
| BHVNBiohaven Ltd. | COM | 1,231,000 | $146.0M | 3.2% | History |
| MRTXMirati Therapeutics, Inc. | COM | 1,393,000 | $114.5M | 2.5% | History |
| ISRGIntuitive Surgical Inc | COM NEW | 325,000 | $98.0M | 2.2% | History |
| ACETAdicet Bio, Inc. | COM | 3,120,000 | $62.3M | 1.4% | History |
| EWEdwards Lifesciences Corp | Stock | 440,000 | $51.8M | 1.1% | History |
| BHCBausch Health Companies Inc. | Stock | 1,694,700 | $38.7M | 0.9% | History |
| INSMINSMED Inc | COM PAR $.01 | 1,354,539 | $31.8M | 0.7% | History |
| ChemoCentryx, Inc.16383L106 | COM | 1,175,000 | $29.5M | 0.7% | – |
| AXSMAxsome Therapeutics, Inc. | COM | 711,000 | $29.4M | 0.7% | History |
| RCUSArcus Biosciences, Inc. | COM | 912,000 | $28.8M | 0.6% | History |
| PENPenumbra Inc | COM | 104,000 | $23.1M | 0.5% | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,040,000 | $19.2M | 0.4% | History |
| BPMCBlueprint Medicines Corp | COM | 291,184 | $18.6M | 0.4% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 215,000 | $13.3M | 0.3% | History |
| Dynamics Special Purpose Cor268010105 | CLASS A COM | 500,000 | $4.93M | 0.1% | – |
| MLTXMoonLake Immunotherapeutics | COM CL A | 400,000 | $4.44M | 0.1% | History |
| GRTSGritstone bio, Inc. | COM | 560,000 | $2.31M | 0.1% | History |